(Note: not an initial public offering): Prior to this offering, our Class A Common Stock has not been traded on an established public trading market, although quotations for our Class A Common Stock   were reported on the OTC Pink, or the Pink Open Market, under the symbol “PFHD.”) We are a financial holding company incorporated in 2014 […]

  We are a late-stage biopharmaceutical company focused on developing and commercializing treatments for dermatological diseases with high unmet medical needs. Our current portfolio is comprised of topical treatments with significant potential to address immune-mediated dermatological diseases and conditions, or immuno-dermatology. Our strategy is to identify and develop treatments against validated biological targets in dermatology […]

  Our vision is to delight millions of members with better health and better care while reducing the total cost of care. Our mission is to transform health care for all through our human-centered, technology-powered model. We are a membership-based primary care platform with seamless digital health and inviting in-office care, convenient to where people […]

  We are a precision oncology medicine company pioneering the discovery and development of small molecule, tumor-agnostic therapies. We target undrugged oncogenic driver mutations in patients with genetically-defined cancers. The foundation of our company is built upon a deep understanding of cancer genetics, protein structure and function, and medicinal chemistry. Our proprietary technology platform, which […]

  We will seek to capitalize on the experience and networks of our management team, Mr. Wenhui Xiong, Mr. Jianjun Nie, Mr. H. David Sherman, Mr. Jianjun Lu and Ms. Li Wan, the prospectus says. Our team consists of seasoned and experienced professionals who have experience in equity investments, finance, business operations and management, as […]

  We are a high-growth, healthcare and wellness company that sells topical products to improve immune health, neuromuscular health and skin barrier health. Using our proprietary platform, which we call our Bionome Engineered Platform, we develop products that target the institutional care and self-care markets. We believe there is significant unmet global demand for non-prescription […]

(Note – not an IPO: The common shares are listed on the Norwegian Over-The-Counter List (the “N-OTC”), an over-the-counter market that is administered and operated by a subsidiary of the Norwegian Securities Dealers Association.) We are a leading international owner and operator of dry bulk vessels, and one of the world’s largest owners of Capesize […]

  Our initial business combination and value creation strategy will be to identify, acquire and, after our initial business combination, assist in the growth of a business in the cannabis industry.

  We believe we are particularly well-positioned to capitalize on growing opportunities created by consumer/lifestyle assets. We will not undertake our initial business combination with any entity with its principal business operations in China. We do not have any specific business combination under consideration and we have not (nor has anyone on our behalf), directly […]

We are a newly formed commercial real estate finance company. Our strategy is to originate, structure and invest in first mortgage loans, mezzanine loans, preferred equity and alternative structured financings in commercial real estate properties, as well as multifamily commercial mortgage backed securities, or CMBS, securitizations, or collectively our target assets. We will primarily focus […]